FAM
FDMT icon

Fred Alger Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Fred Alger Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,241
Closed -$139K – 541
2022
Q4 		$139K Buy
+6,241
New +$96.4K ﹤0.01% 439

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Fred Alger Management's FDMT Position: Q1 2023 in Review

Fred Alger Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2023, closing a stake of 6,241 shares — an estimated $139K sold.

Fred Alger Management first reported a position in FDMT in Q4 2022 and held it in 1 quarter. The position peaked at $139K in Q4 2022. 94 funds tracked by Wall St. Rank hold FDMT as of Q1 2023.

  • Fred Alger Management reported no remaining 4D Molecular Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Fred Alger Management sold 6,241 4D Molecular Therapeutics shares in Q1 2023, an estimated $139K.
  • Fred Alger Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 1 quarter.
  • Fred Alger Management's 4D Molecular Therapeutics position peaked at $139K in Q4 2022.
  • 94 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2023.

Based on Fred Alger Management's 13F filing for Q1 2023, filed 15 May 2023.